| abstract |
The present invention relates to a conjugate comprising an insulin-like growth factor-1 (IGF-I) variant and one or two poly (ethylene glycol) groups, wherein the IGF-I variant is an amino acid of a wild type IGF-I amino acid sequence. Up to 3 of positions 27, 37, 65, and 68 have one or two of these amino acid sequences lysine, have an amino acid variation such that amino acid 27 is a polar amino acid that is not lysine, and is conjugated via a primary amino group of lysine, Disclosed is a conjugate wherein the poly (ethylene glycol) group has a total molecular weight of 20 to 100 kDa. The conjugates of the present invention are useful for the treatment of neurodegenerative disorders such as Alzheimer's disease. |